Notice: Global Information Announces Listing on JASDAQ Standard Market of the Tokyo Stock Exchange

Cover Image
Market Research Report

HIV Disease Coverage Forecast and Market Analysis to 2024

Published by Datamonitor Healthcare Product code 633173
Published Content info 717 Pages
Delivery time: 1-2 business days
Price
Back to Top
HIV Disease Coverage Forecast and Market Analysis to 2024
Published: January 25, 2019 Content info: 717 Pages
Description

Overview

The human immunodeficiency virus, or HIV, is a retrovirus that infects the cells of the immune system such as T lymphocytes, specifically cluster of differentiation-4+ T cells, dendritic cells, and macrophages. Infection leads to a progressive weakening of the immune system and ultimately results in acquired immunodeficiency syndrome (AIDS).

Market Snapshot

  • B/F/TAF will drive significant revenue growth due to its attractive combination of an INSTI and a preferred backbone.
  • TAF-based regimens are rapidly cannibalizing the share of TDF-based products due to superior renal and bone safety.
  • HIV prevalence is increasing in the analyzed markets as people are living longer on antiretroviral therapy.
  • Rapid uptake of TAF-based regimens in the US will protect Gilead's revenues following TDF patent expiry.
  • B/F/TAF's potency and clean tolerability profile will outcompete its rivals, restricting their uptake at launch.
Table of Contents
Product Code: DMKC 5240

TABLE OF CONTENTS

FORECAST: HIV (Published on 22 December 2017)

  • OVERVIEW
  • EXECUTIVE SUMMARY
  • MARKET DYNAMICS
  • FORECAST AND FUTURE TRENDS
  • MARKET DEFINITION AND METHODOLOGY
  • PRIMARY RESEARCH METHODOLOGY
  • BIBLIOGRAPHY
  • PRODUCT PROFILE: ATRIPLA
  • PRODUCT PROFILE (LATE STAGE): B/F/TAF
  • PRODUCT PROFILE: COMPLERA
  • PRODUCT PROFILE (LATE STAGE): DOR/3TC/TDF
  • PRODUCT PROFILE: DESCOVY
  • PRODUCT PROFILE: GENVOYA
  • PRODUCT PROFILE: ISENTRESS
  • PRODUCT PROFILE: JULUCA
  • PRODUCT PROFILE: ODEFSEY
  • PRODUCT PROFILE: PREZISTA FRANCHISE
  • PRODUCT PROFILE: REYATAZ FRANCHISE
  • PRODUCT PROFILE: STRIBILD
  • PRODUCT PROFILE: SYMTUZA
  • PRODUCT PROFILE: TIVICAY
  • PRODUCT PROFILE (LATE STAGE): TIVICAY/EPIVIR
  • PRODUCT PROFILE: TRIUMEQ
  • PRODUCT PROFILE: TRUVADA
  • PRODUCT PROFILE (LATE STAGE): CABOTEGRAVIR/RILPIVIRINE
  • PRODUCT PROFILE (LATE STAGE): FOSTEMSAVIR

TREATMENT: HIV (Published on 13 April 2018)

  • OVERVIEW
  • PRIMARY RESEARCH METHODOLOGY
  • DISEASE DEFINITION AND DIAGNOSIS
  • PATIENT SEGMENTATION
  • CURRENT TREATMENT OPTIONS
  • TREATMENT GUIDELINES
  • PRESCRIBING TRENDS
  • UNMET NEEDS IN HIV
  • IMPACT OF GENERICS

EPIDEMIOLOGY: HIV (Published on 25 January 2019)

  • OVERVIEW
  • DISEASE BACKGROUND
  • METHODOLOGY
  • FORECAST
  • BIBLIOGRAPHY
  • APPENDIX: ADDITIONAL SOURCES

MARKETED DRUGS: HIV (Published on 22 December 2017)

  • OVERVIEW
  • EXECUTIVE SUMMARY
  • PRODUCT OVERVIEW
  • PRODUCT PROFILE: ATRIPLA
  • PRODUCT PROFILE: COMPLERA
  • PRODUCT PROFILE: DESCOVY
  • PRODUCT PROFILE: GENVOYA
  • PRODUCT PROFILE: ISENTRESS
  • PRODUCT PROFILE: JULUCA
  • PRODUCT PROFILE: ODEFSEY
  • PRODUCT PROFILE: PREZISTA FRANCHISE
  • PRODUCT PROFILE: REYATAZ FRANCHISE
  • PRODUCT PROFILE: STRIBILD
  • PRODUCT PROFILE: SYMTUZA
  • PRODUCT PROFILE: TIVICAY
  • PRODUCT PROFILE: TRIUMEQ
  • PRODUCT PROFILE: TRUVADA

PIPELINE: HIV (Published on 22 December 2017)

  • OVERVIEW
  • EXECUTIVE SUMMARY
  • CLINICAL PIPELINE OVERVIEW
  • ADDITIONAL PHARMA INTELLIGENCE PIPELINE RESOURCES
  • PRODUCT PROFILE (LATE STAGE): B/F/TAF
  • PRODUCT PROFILE (LATE STAGE): DOR/3TC/TDF
  • PRODUCT PROFILE (LATE STAGE): TIVICAY/EPIVIR
  • PRODUCT PROFILE (LATE STAGE): CABOTEGRAVIR/RILPIVIRINE
  • PRODUCT PROFILE (LATE STAGE): FOSTEMSAVIR

LIST OF FIGURES

  • Figure 1: HIV - current and future market dynamics analysis
  • Figure 2: Datamonitor Healthcare's assessment summary of key marketed and pipeline drugs for HIV
  • Figure 3: HIV total market value across the US and five major EU markets, by country, 2017-26
  • Figure 4: HIV total market value across the US and five major EU markets, by class, 2017-26
  • Figure 5: HIV sales in the US, 2017-26
  • Figure 6: HIV sales in the five major EU markets, by country, 2017-26
  • Figure 7: Sales of B/F/TAF compared to INSTI-based STRs and injections, by product, 2017-26
  • Figure 8: Sales of ViiV Healthcare's oral two-drug regimens compared to B/F/TAF and Symtuza, by product, 2017-26
  • Figure 9: HIV sales across the US and five major EU markets, by company, 2017-26
  • Figure 10: Datamonitor Healthcare's HIV forecast methodology
  • Figure 11: Price sources and calculations, by country
  • Figure 12: Atripla for HIV - SWOT analysis
  • Figure 13: Datamonitor Healthcare's drug assessment summary of Atripla for HIV
  • Figure 14: Datamonitor Healthcare's drug assessment summary of Atripla for HIV
  • Figure 15: Atripla sales for HIV across the US and five major EU markets, by country, 2017-26
  • Figure 16: B/F/TAF for HIV - SWOT analysis
  • Figure 17: Datamonitor Healthcare's drug assessment summary of B/F/TAF for HIV
  • Figure 18: Datamonitor Healthcare's drug assessment summary of B/F/TAF for HIV
  • Figure 19: B/F/TAF sales for HIV across the US and five major EU markets, by country, 2017-26
  • Figure 20: Complera for HIV - SWOT analysis
  • Figure 21: Datamonitor Healthcare's drug assessment summary of Complera for HIV
  • Figure 22: Datamonitor Healthcare's drug assessment summary of Complera for HIV
  • Figure 23: Complera sales for HIV across the US and five major EU markets, by country, 2017-26
  • Figure 24: DOR/3TC/TDF for HIV - SWOT analysis
  • Figure 25: Datamonitor Healthcare's drug assessment summary of DOR/3TC/TDF for HIV
  • Figure 26: Datamonitor Healthcare's drug assessment summary of DOR/3TC/TDF for HIV
  • Figure 27: DOR/3TC/TDF sales for HIV across the US and five major EU markets, by country, 2017-26
  • Figure 28: Descovy for HIV - SWOT analysis
  • Figure 29: Datamonitor Healthcare's drug assessment summary of Descovy for HIV
  • Figure 30: Datamonitor Healthcare's drug assessment summary of Descovy for HIV
  • Figure 31: Descovy sales for HIV across the US and five major EU markets, by country, 2017-26
  • Figure 32: Genvoya for HIV - SWOT analysis
  • Figure 33: Datamonitor Healthcare's drug assessment summary of Genvoya for HIV
  • Figure 34: Datamonitor Healthcare's drug assessment summary of Genvoya for HIV
  • Figure 35: Genvoya sales for HIV across the US and five major EU markets, by country, 2017-26
  • Figure 36: Isentress for HIV - SWOT analysis
  • Figure 37: Datamonitor Healthcare's drug assessment summary of Isentress for HIV
  • Figure 38: Datamonitor Healthcare's drug assessment summary of Isentress for HIV
  • Figure 39: Isentress sales for HIV across the US and five major EU markets, by country, 2017-26
  • Figure 40: Juluca for HIV - SWOT analysis
  • Figure 41: Datamonitor Healthcare's drug assessment summary of Juluca for HIV
  • Figure 42: Datamonitor Healthcare's drug assessment summary of Juluca for HIV
  • Figure 43: Juluca sales for HIV across the US and five major EU markets, by country, 2017-26
  • Figure 44: Odefsey for HIV - SWOT analysis
  • Figure 45: Datamonitor Healthcare's drug assessment summary of Odefsey for HIV
  • Figure 46: Datamonitor Healthcare's drug assessment summary of Odefsey for HIV
  • Figure 47: Odefsey sales for HIV across the US and five major EU markets, by country, 2017-26
  • Figure 48: Prezista franchise for HIV - SWOT analysis
  • Figure 49: Datamonitor Healthcare's drug assessment summary of Prezista franchise for HIV
  • Figure 50: Datamonitor Healthcare's drug assessment summary of Prezista franchise for HIV
  • Figure 51: Prezista sales for HIV across the US and five major EU markets, by country, 2017-26
  • Figure 52: Prezcobix sales for HIV across the US and five major EU markets, by country, 2017-26
  • Figure 53: Reyataz franchise for HIV - SWOT analysis
  • Figure 54: Datamonitor Healthcare's drug assessment summary of Reyataz franchise for HIV
  • Figure 55: Datamonitor Healthcare's drug assessment summary of Reyataz franchise for HIV
  • Figure 56: Reyataz sales for HIV across the US and five major EU markets, by country, 2017-26
  • Figure 57: Evotaz sales for HIV across the US and five major EU markets, by country, 2017-26
  • Figure 58: Stribild for HIV - SWOT analysis
  • Figure 59: Datamonitor Healthcare's drug assessment summary of Stribild for HIV
  • Figure 60: Datamonitor Healthcare's drug assessment summary of Stribild for HIV
  • Figure 61: Stribild sales for HIV across the US and five major EU markets, by country, 2017-26
  • Figure 62: Symtuza for HIV - SWOT analysis
  • Figure 63: Datamonitor Healthcare's drug assessment summary of Symtuza for HIV
  • Figure 64: Datamonitor Healthcare's drug assessment summary of Symtuza for HIV
  • Figure 65: Symtuza sales for HIV across the US and five major EU markets, by country, 2017-26
  • Figure 66: Tivicay for HIV - SWOT analysis
  • Figure 67: Datamonitor Healthcare's drug assessment summary of Tivicay for HIV
  • Figure 68: Datamonitor Healthcare's drug assessment summary of Tivicay for HIV
  • Figure 69: Tivicay sales for HIV across the US and five major EU markets, by country, 2017-26
  • Figure 70: Tivicay/Epivir for HIV - SWOT analysis
  • Figure 71: Datamonitor Healthcare's drug assessment summary of Tivicay/Epivir for HIV
  • Figure 72: Datamonitor Healthcare's drug assessment summary of Tivicay/Epivir for HIV
  • Figure 73: Tivicay/Epivir sales for HIV across the US and five major EU markets, by country, 2017-26
  • Figure 74: Triumeq for HIV - SWOT analysis
  • Figure 75: Datamonitor Healthcare's drug assessment summary of Triumeq for HIV
  • Figure 76: Datamonitor Healthcare's drug assessment summary of Triumeq for HIV
  • Figure 77: Triumeq sales for HIV across the US and five major EU markets, by country, 2017-26
  • Figure 78: Truvada for HIV - SWOT analysis
  • Figure 79: Datamonitor Healthcare's drug assessment summary of Truvada for HIV
  • Figure 80: Datamonitor Healthcare's drug assessment summary of Truvada for HIV
  • Figure 81: Truvada sales for HIV across the US and five major EU markets, by country, 2017-26
  • Figure 82: Cabotegravir/rilpivirine for HIV - SWOT analysis
  • Figure 83: Datamonitor Healthcare's drug assessment summary of cabotegravir/rilpivirine for HIV
  • Figure 84: Datamonitor Healthcare's drug assessment summary of cabotegravir/rilpivirine for HIV
  • Figure 85: Cabotegravir/rilpivirine sales for HIV across the US and five major EU markets, by country, 2017-26
  • Figure 86: Fostemsavir for HIV - SWOT analysis
  • Figure 87: Datamonitor Healthcare's drug assessment summary of fostemsavir for HIV
  • Figure 88: Datamonitor Healthcare's drug assessment summary of fostemsavir for HIV
  • Figure 89: Fostemsavir sales for HIV across the US and five major EU markets, by country, 2017-26
  • Figure 90: Percentage of HIV prevalent population who are diagnosed and undiagnosed in the US and five major EU markets, by country
  • Figure 91: Percentage of the HIV-diagnosed population under physician care in the US and five major EU markets, by country
  • Figure 92: Breakdown of pharmacologically treated HIV patients in the US and five major EU markets, by line of therapy and country
  • Figure 93: Percentage of respondents in the US and five major EU markets who agree with initiating treatment in all patients, by country
  • Figure 94: Treatment status of HIV patients under physician care in the US and five major EU markets, by country
  • Figure 95: Top five brands used for the treatment of first-line HIV patients, by country
  • Figure 96: Top five regimens used for the treatment of first-line HIV patients, by country
  • Figure 97: Top five regimens used for the treatment of second-line HIV patients, by country
  • Figure 98: Top five brands used for the treatment of second-line HIV patients, by country
  • Figure 99: Top five regimens used for the treatment of third-line HIV patients, by country
  • Figure 100: Top five brands used for the treatment of third-line HIV patients, by country
  • Figure 101: Top five regimens used for the treatment of fourth-line and beyond HIV patients, by country
  • Figure 102: Top five brands used for the treatment of fourth-line and beyond HIV patients, by country
  • Figure 103: Relative importance of unmet needs in HIV treatment in the US and five major EU markets, by country
  • Figure 104: Physician views on potential adherence impact of breaking up FDCs in HIV in the US and five major EU markets, by country
  • Figure 105: Extent of physician comfort with breaking up FDCs to prescribe separate generic components in HIV in the US and five major EU markets, by country
  • Figure 106: Physician views on whether cost savings justify the breaking up of FDCs in HIV in the US and five major EU markets, by country
  • Figure 107: Atripla for HIV - SWOT analysis
  • Figure 108: Datamonitor Healthcare's drug assessment summary of Atripla for HIV
  • Figure 109: Datamonitor Healthcare's drug assessment summary of Atripla for HIV
  • Figure 110: Atripla sales for HIV across the US and five major EU markets, by country, 2017-26
  • Figure 111: Complera for HIV - SWOT analysis
  • Figure 112: Datamonitor Healthcare's drug assessment summary of Complera for HIV
  • Figure 113: Datamonitor Healthcare's drug assessment summary of Complera for HIV
  • Figure 114: Complera sales for HIV across the US and five major EU markets, by country, 2017-26
  • Figure 115: Descovy for HIV - SWOT analysis
  • Figure 116: Datamonitor Healthcare's drug assessment summary of Descovy for HIV
  • Figure 117: Datamonitor Healthcare's drug assessment summary of Descovy for HIV
  • Figure 118: Descovy sales for HIV across the US and five major EU markets, by country, 2017-26
  • Figure 119: Genvoya for HIV - SWOT analysis
  • Figure 120: Datamonitor Healthcare's drug assessment summary of Genvoya for HIV
  • Figure 121: Datamonitor Healthcare's drug assessment summary of Genvoya for HIV
  • Figure 122: Genvoya sales for HIV across the US and five major EU markets, by country, 2017-26
  • Figure 123: Isentress for HIV - SWOT analysis
  • Figure 124: Datamonitor Healthcare's drug assessment summary of Isentress for HIV
  • Figure 125: Datamonitor Healthcare's drug assessment summary of Isentress for HIV
  • Figure 126: Isentress sales for HIV across the US and five major EU markets, by country, 2017-26
  • Figure 127: Juluca for HIV - SWOT analysis
  • Figure 128: Datamonitor Healthcare's drug assessment summary of Juluca for HIV
  • Figure 129: Datamonitor Healthcare's drug assessment summary of Juluca for HIV
  • Figure 130: Juluca sales for HIV across the US and five major EU markets, by country, 2017-26
  • Figure 131: Odefsey for HIV - SWOT analysis
  • Figure 132: Datamonitor Healthcare's drug assessment summary of Odefsey for HIV
  • Figure 133: Datamonitor Healthcare's drug assessment summary of Odefsey for HIV
  • Figure 134: Odefsey sales for HIV across the US and five major EU markets, by country, 2017-26
  • Figure 135: Prezista franchise for HIV - SWOT analysis
  • Figure 136: Datamonitor Healthcare's drug assessment summary of Prezista franchise for HIV
  • Figure 137: Datamonitor Healthcare's drug assessment summary of Prezista franchise for HIV
  • Figure 138: Prezista sales for HIV across the US and five major EU markets, by country, 2017-26
  • Figure 139: Prezcobix sales for HIV across the US and five major EU markets, by country, 2017-26
  • Figure 140: Reyataz franchise for HIV - SWOT analysis
  • Figure 141: Datamonitor Healthcare's drug assessment summary of Reyataz franchise for HIV
  • Figure 142: Datamonitor Healthcare's drug assessment summary of Reyataz franchise for HIV
  • Figure 143: Reyataz sales for HIV across the US and five major EU markets, by country, 2017-26
  • Figure 144: Evotaz sales for HIV across the US and five major EU markets, by country, 2017-26
  • Figure 145: Stribild for HIV - SWOT analysis
  • Figure 146: Datamonitor Healthcare's drug assessment summary of Stribild for HIV
  • Figure 147: Datamonitor Healthcare's drug assessment summary of Stribild for HIV
  • Figure 148: Stribild sales for HIV across the US and five major EU markets, by country, 2017-26
  • Figure 149: Symtuza for HIV - SWOT analysis
  • Figure 150: Datamonitor Healthcare's drug assessment summary of Symtuza for HIV
  • Figure 151: Datamonitor Healthcare's drug assessment summary of Symtuza for HIV
  • Figure 152: Symtuza sales for HIV across the US and five major EU markets, by country, 2017-26
  • Figure 153: Tivicay for HIV - SWOT analysis
  • Figure 154: Datamonitor Healthcare's drug assessment summary of Tivicay for HIV
  • Figure 155: Datamonitor Healthcare's drug assessment summary of Tivicay for HIV
  • Figure 156: Tivicay sales for HIV across the US and five major EU markets, by country, 2017-26
  • Figure 157: Triumeq for HIV - SWOT analysis
  • Figure 158: Datamonitor Healthcare's drug assessment summary of Triumeq for HIV
  • Figure 159: Datamonitor Healthcare's drug assessment summary of Triumeq for HIV
  • Figure 160: Triumeq sales for HIV across the US and five major EU markets, by country, 2017-26
  • Figure 161: Truvada for HIV - SWOT analysis
  • Figure 162: Datamonitor Healthcare's drug assessment summary of Truvada for HIV
  • Figure 163: Datamonitor Healthcare's drug assessment summary of Truvada for HIV
  • Figure 164: Truvada sales for HIV across the US and five major EU markets, by country, 2017-26
  • Figure 165: B/F/TAF for HIV - SWOT analysis
  • Figure 166: Datamonitor Healthcare's drug assessment summary of B/F/TAF for HIV
  • Figure 167: Datamonitor Healthcare's drug assessment summary of B/F/TAF for HIV
  • Figure 168: B/F/TAF sales for HIV across the US and five major EU markets, by country, 2017-26
  • Figure 169: DOR/3TC/TDF for HIV - SWOT analysis
  • Figure 170: Datamonitor Healthcare's drug assessment summary of DOR/3TC/TDF for HIV
  • Figure 171: Datamonitor Healthcare's drug assessment summary of DOR/3TC/TDF for HIV
  • Figure 172: DOR/3TC/TDF sales for HIV across the US and five major EU markets, by country, 2017-26
  • Figure 173: Tivicay/Epivir for HIV - SWOT analysis
  • Figure 174: Datamonitor Healthcare's drug assessment summary of Tivicay/Epivir for HIV
  • Figure 175: Datamonitor Healthcare's drug assessment summary of Tivicay/Epivir for HIV
  • Figure 176: Tivicay/Epivir sales for HIV across the US and five major EU markets, by country, 2017-26
  • Figure 177: Cabotegravir/rilpivirine for HIV - SWOT analysis
  • Figure 178: Datamonitor Healthcare's drug assessment summary of cabotegravir/rilpivirine for HIV
  • Figure 179: Datamonitor Healthcare's drug assessment summary of cabotegravir/rilpivirine for HIV
  • Figure 180: Cabotegravir/rilpivirine sales for HIV across the US and five major EU markets, by country, 2017-26
  • Figure 181: Fostemsavir for HIV - SWOT analysis
  • Figure 182: Datamonitor Healthcare's drug assessment summary of fostemsavir for HIV
  • Figure 183: Datamonitor Healthcare's drug assessment summary of fostemsavir for HIV
  • Figure 184: Fostemsavir sales for HIV across the US and five major EU markets, by country, 2017-26

LIST OF TABLES

  • Table 1: HIV sales across the US and five major EU markets, by company ($m), 2017-26
  • Table 2: Molecules and brands included in Datamonitor Healthcare's patient-based HIV forecast
  • Table 3: Exchange rates used for calculating prices
  • Table 4: Infectious disease specialists surveyed for the HIV primary research study, 2017
  • Table 5: Atripla drug profile
  • Table 6: Atripla pivotal data in HIV
  • Table 7: Atripla sales for HIV across the US and five major EU markets, by country ($m), 2017-26
  • Table 8: B/F/TAF drug profile
  • Table 9: B/F/TAF Phase III data in HIV
  • Table 10: B/F/TAF Phase III trials in HIV
  • Table 11: B/F/TAF sales for HIV across the US and five major EU markets, by country ($m), 2017-26
  • Table 12: Complera drug profile
  • Table 13: Complera pivotal data in HIV
  • Table 14: Complera other late-phase trial data in HIV
  • Table 15: Complera sales for HIV across the US and five major EU markets, by country ($m), 2017-26
  • Table 16: DOR/3TC/TDF drug profile
  • Table 17: DOR/3TC/TDF Phase III data in HIV
  • Table 18: DOR/3TC/TDF Phase III trials in HIV
  • Table 19: Doravirine Phase III trials in HIV
  • Table 20: DOR/3TC/TDF sales for HIV across the US and five major EU markets, by country ($m), 2017-26
  • Table 21: Descovy drug profile
  • Table 22: Descovy pivotal data in HIV
  • Table 23: Descovy other late-phase trials in HIV
  • Table 24: Descovy sales for HIV across the US and five major EU markets, by country ($m), 2017-26
  • Table 25: Genvoya drug profile
  • Table 26: Genvoya pivotal data in HIV
  • Table 27: Genvoya other late-phase data in HIV
  • Table 28: Genvoya ongoing late-phase trials in HIV
  • Table 29: Genvoya sales for HIV across the US and five major EU markets, by country ($m), 2017-26
  • Table 30: Isentress drug profile
  • Table 31: Isentress pivotal data in HIV
  • Table 32: Isentress sales for HIV across the US and five major EU markets, by country ($m), 2017-26
  • Table 33: Juluca drug profile
  • Table 34: Juluca Phase III data in HIV
  • Table 35: Juluca sales for HIV across the US and five major EU markets, by country ($m), 2017-26
  • Table 36: Odefsey drug profile
  • Table 37: Odefsey pivotal data in HIV
  • Table 38: Odefsey other late-phase data in HIV
  • Table 39: Odefsey sales for HIV across the US and five major EU markets, by country ($m), 2017-26
  • Table 40: Prezista drug profile
  • Table 41: Prezcobix drug profile
  • Table 42: Prezista pivotal data in HIV
  • Table 43: Prezista pivotal data in HIV
  • Table 44: Prezista sales for HIV across the US and five major EU markets, by country ($m), 2017-26
  • Table 45: Prezcobix sales for HIV across the US and five major EU markets, by country ($m), 2017-26
  • Table 46: Reyataz drug profile
  • Table 47: Evotaz drug profile
  • Table 48: Reyataz pivotal data in HIV
  • Table 49: Reyataz other late-phase data in HIV
  • Table 50: Reyataz other late-phase data in HIV
  • Table 51: Reyataz sales for HIV across the US and five major EU markets, by country ($m), 2017-26
  • Table 52: Evotaz sales for HIV across the US and five major EU markets, by country ($m), 2017-26
  • Table 53: Stribild drug profile
  • Table 54: Stribild pivotal data in HIV
  • Table 55: Stribild other late-phase data in HIV
  • Table 56: Stribild sales for HIV across the US and five major EU markets, by country ($m), 2017-26
  • Table 57: Symtuza drug profile
  • Table 58: Symtuza pivotal data in HIV
  • Table 59: Symtuza sales for HIV across the US and five major EU markets, by country ($m), 2017-26
  • Table 60: Tivicay drug profile
  • Table 61: Tivicay pivotal data in HIV
  • Table 62: Tivicay pivotal data in HIV
  • Table 63: Tivicay ongoing late-phase clinical trials in HIV
  • Table 64: Tivicay sales for HIV across the US and five major EU markets, by country ($m), 2017-26
  • Table 65: Tivicay/Epivir drug profile
  • Table 66: Tivicay/Epivir Phase III trials in HIV
  • Table 67: Tivicay/Epivir Phase II data in HIV
  • Table 68: Tivicay/Epivir sales for HIV across the US and five major EU markets, by country ($m), 2017-26
  • Table 69: Triumeq drug profile
  • Table 70: Triumeq pivotal data in HIV
  • Table 71: Triumeq other late-phase data in HIV
  • Table 72: Triumeq sales for HIV across the US and five major EU markets, by country ($m), 2017-26
  • Table 73: Truvada drug profile
  • Table 74: Truvada pivotal data in HIV
  • Table 75: Truvada pivotal data in HIV
  • Table 76: Truvada sales for HIV across the US and five major EU markets, by country ($m), 2017-26
  • Table 77: Cabotegravir/rilpivirine drug profile
  • Table 78: Cabotegravir/rilpivirine Phase III trials in HIV
  • Table 79: Cabotegravir/rilpivirine sales for HIV across the US and five major EU markets, by country ($m), 2017-26
  • Table 80: Fostemsavir drug profile
  • Table 81: Fostemsavir Phase III trial in HIV
  • Table 82: Fostemsavir Phase II data in HIV
  • Table 83: Fostemsavir sales for HIV across the US and five major EU markets, by country ($m), 2017-26
  • Table 84: Infectious disease specialists surveyed for the HIV primary research study, 2017
  • Table 85: Therapies discussed in the HIV key opinion leader primary research study, 2017
  • Table 86: HIV total infections, new infections, and AIDS-attributable deaths, by region, 2016
  • Table 87: New HIV diagnoses in the US and five major EU markets, by transmission route, 2016
  • Table 88: Per-act HIV transmission risk, by transmission route
  • Table 89: CDC classification system for HIV-infected adults and adolescents
  • Table 90: Symptomatic conditions included in CDC HIV classification system clinical categories
  • Table 91: WHO clinical staging of HIV/AIDS for adults and adolescents
  • Table 92: Treatments available for HIV across the US and five major EU markets
  • Table 93: Summary of "recommended" treatment options in HHS and EACS treatment guidelines
  • Table 94: HIV prevalence, infections, and AIDS-attributable deaths in 2017, by region
  • Table 95: Sources used for the epidemiological analysis of HIV in the US, Japan, and five major EU markets, by country
  • Table 96: Data sources used to describe the diagnosed prevalent HIV population, by country
  • Table 97: Data sources used to segment diagnosed incident HIV cases by AIDS at diagnosis, by country
  • Table 98: Data sources used to segment diagnosed incident HIV cases by transmission category, by country
  • Table 99: Diagnosed incident cases of HIV in the US, Japan, and five major EU markets, by country, 2018-28
  • Table 100: Incident cases of HIV diagnosed at AIDS stage, in adults, in the US, Japan, and five major EU markets, by country, 2018
  • Table 101: Number and proportion of incident HIV cases, by transmission route, and country, 2018
  • Table 102: Total prevalent cases of HIV in the US, Japan, and five major EU markets, by country, 2018-28
  • Table 103: Diagnosed and undiagnosed prevalent HIV cases, by country, 2018
  • Table 104: Co-morbid bone and renal impairments in adult diagnosed prevalent HIV cases, by country, 2018
  • Table 105: Key marketed drugs for HIV
  • Table 106: Atripla drug profile
  • Table 107: Atripla pivotal data in HIV
  • Table 108: Atripla sales for HIV across the US and five major EU markets, by country ($m), 2017-26
  • Table 109: Complera drug profile
  • Table 110: Complera pivotal data in HIV
  • Table 111: Complera other late-phase trial data in HIV
  • Table 112: Complera sales for HIV across the US and five major EU markets, by country ($m), 2017-26
  • Table 113: Descovy drug profile
  • Table 114: Descovy pivotal data in HIV
  • Table 115: Descovy other late-phase trials in HIV
  • Table 116: Descovy sales for HIV across the US and five major EU markets, by country ($m), 2017-26
  • Table 117: Genvoya drug profile
  • Table 118: Genvoya pivotal data in HIV
  • Table 119: Genvoya other late-phase data in HIV
  • Table 120: Genvoya ongoing late-phase trials in HIV
  • Table 121: Genvoya sales for HIV across the US and five major EU markets, by country ($m), 2017-26
  • Table 122: Isentress drug profile
  • Table 123: Isentress pivotal data in HIV
  • Table 124: Isentress sales for HIV across the US and five major EU markets, by country ($m), 2017-26
  • Table 125: Juluca drug profile
  • Table 126: Juluca Phase III data in HIV
  • Table 127: Juluca sales for HIV across the US and five major EU markets, by country ($m), 2017-26
  • Table 128: Odefsey drug profile
  • Table 129: Odefsey pivotal data in HIV
  • Table 130: Odefsey other late-phase data in HIV
  • Table 131: Odefsey sales for HIV across the US and five major EU markets, by country ($m), 2017-26
  • Table 132: Prezista drug profile
  • Table 133: Prezcobix drug profile
  • Table 134: Prezista pivotal data in HIV
  • Table 135: Prezista pivotal data in HIV
  • Table 136: Prezista sales for HIV across the US and five major EU markets, by country ($m), 2017-26
  • Table 137: Prezcobix sales for HIV across the US and five major EU markets, by country ($m), 2017-26
  • Table 138: Reyataz drug profile
  • Table 139: Evotaz drug profile
  • Table 140: Reyataz pivotal data in HIV
  • Table 141: Reyataz other late-phase data in HIV
  • Table 142: Reyataz other late-phase data in HIV
  • Table 143: Reyataz sales for HIV across the US and five major EU markets, by country ($m), 2017-26
  • Table 144: Evotaz sales for HIV across the US and five major EU markets, by country ($m), 2017-26
  • Table 145: Stribild drug profile
  • Table 146: Stribild pivotal data in HIV
  • Table 147: Stribild other late-phase data in HIV
  • Table 148: Stribild sales for HIV across the US and five major EU markets, by country ($m), 2017-26
  • Table 149: Symtuza drug profile
  • Table 150: Symtuza pivotal data in HIV
  • Table 151: Symtuza sales for HIV across the US and five major EU markets, by country ($m), 2017-26
  • Table 152: Tivicay drug profile
  • Table 153: Tivicay pivotal data in HIV
  • Table 154: Tivicay pivotal data in HIV
  • Table 155: Tivicay ongoing late-phase clinical trials in HIV
  • Table 156: Tivicay sales for HIV across the US and five major EU markets, by country ($m), 2017-26
  • Table 157: Triumeq drug profile
  • Table 158: Triumeq pivotal data in HIV
  • Table 159: Triumeq other late-phase data in HIV
  • Table 160: Triumeq sales for HIV across the US and five major EU markets, by country ($m), 2017-26
  • Table 161: Truvada drug profile
  • Table 162: Truvada pivotal data in HIV
  • Table 163: Truvada pivotal data in HIV
  • Table 164: Truvada sales for HIV across the US and five major EU markets, by country ($m), 2017-26
  • Table 165: Key Phase III pipeline products in development for HIV
  • Table 166: B/F/TAF drug profile
  • Table 167: B/F/TAF Phase III data in HIV
  • Table 168: B/F/TAF Phase III trials in HIV
  • Table 169: B/F/TAF sales for HIV across the US and five major EU markets, by country ($m), 2017-26
  • Table 170: DOR/3TC/TDF drug profile
  • Table 171: DOR/3TC/TDF Phase III data in HIV
  • Table 172: DOR/3TC/TDF Phase III trials in HIV
  • Table 173: Doravirine Phase III trials in HIV
  • Table 174: DOR/3TC/TDF sales for HIV across the US and five major EU markets, by country ($m), 2017-26
  • Table 175: Tivicay/Epivir drug profile
  • Table 176: Tivicay/Epivir Phase III trials in HIV
  • Table 177: Tivicay/Epivir Phase II data in HIV
  • Table 178: Tivicay/Epivir sales for HIV across the US and five major EU markets, by country ($m), 2017-26
  • Table 179: Cabotegravir/rilpivirine drug profile
  • Table 180: Cabotegravir/rilpivirine Phase III trials in HIV
  • Table 181: Cabotegravir/rilpivirine sales for HIV across the US and five major EU markets, by country ($m), 2017-26
  • Table 182: Fostemsavir drug profile
  • Table 183: Fostemsavir Phase III trial in HIV
  • Table 184: Fostemsavir Phase II data in HIV
  • Table 185: Fostemsavir sales for HIV across the US and five major EU markets, by country ($m), 2017-26
Back to Top